Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

被引：0

作者：

Joan Maurel

Santiago Sánchez-Cabús

Berta Laquente

Lydia Gaba

Laura Visa

Joan Fabregat

Ignacio Povés

Susana Roselló

Roberto Díaz-Beveridge

Marta Martín-Richard

Javier Rodriguez

Luis Sabater

Carles Conill

María Cambray

Ana Reig

Juan Ramón Ayuso

Carlos Valls

Antonio Ferrández

Josep Antoni Bombí

Angels Ginés

Xabier García-Albéniz

Laureano Fernández-Cruz

机构：

[1] IDIBAPS,Surgical Department, Hospital Clínic Barcelona

[2] University of Barcelona,Medical Oncology Department

[3] Institut Català d’Oncologia,Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group

[4] IDIBAPS,Department of Oncology

[5] University of Barcelona,Surgical Department

[6] Hospital Mar,Surgical Department

[7] Hospital Bellvitge,Medical Oncology Department

[8] Hospital del Mar,Medical Oncology Department

[9] Hospital Clínico Valencia,Medical Oncology Department

[10] Hospital La Fe,Medical Oncology Department

[11] Hospital Sant Pau,Surgical Department

[12] Hospital Clínico Universitario Navarra,Radiotherapy Oncology Department, Hospital Clínic Barcelona

[13] Hospital Clínico Valencia,Radiotherapy Oncology Department

[14] IDIBAPS,Radiotherapy Oncology Department

[15] University of Barcelona,Radiology Department, Hospital Clínic Barcelona

[16] Institut Català d’Oncologia,Radiology Department

[17] Hospital Mar,Pathology Department

[18] IDIBAPS,Pathology Department, Hospital Clínic Barcelona

[19] University of Barcelona,Gastrointestinal Department, Hospital Clínic Barcelona

[20] Hospital Bellvitge,undefined

[21] Hospital Clínico Valencia,undefined

[22] IDIBAPS,undefined

[23] University of Barcelona,undefined

[24] IDIBAPS,undefined

[25] University of Barcelona,undefined

[26] Harvard T.H. Chan School of Public Health,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2018年 / 82卷

关键词：

Neoadjuant; Pancreatic; Adenocarcinoma;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：935 / 943

页数：8

共 50 条

[41] Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in advanced pancreatic cancer patients
Shinohara, Akira
Okuyama, Hiroyuki
Kuwahara, Akiko
Kobayashi, Misaki
Takahashi, Hideaki
Ohno, Izumi
Shimizu, Satoshi
Mitsunaga, Shuichi
Saitoh, Shinichiro
Ikeda, Masafumi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[42] Impact of Neoadjuvant Chemotherapy With Gemcitabine Plus Nab-paclitaxel on the Treatment for Borderline Resectable Pancreatic Cancer
Miyasaka, Y.
Ohtsuka, T.
Kimura, R.
Mori, Y.
Nakata, K.
Nakamura, M.
PANCREAS, 2019, 48 (10) : 1492 - 1492
[43] Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Q. P. Janssen
J. L. van Dam
B. A. Bonsing
H. Bos
K. P. Bosscha
P. P. L. O. Coene
C. H. J. van Eijck
I. H. J. T. de Hingh
T. M. Karsten
M. B. van der Kolk
G. A. Patijn
M. S. L. Liem
H. C. van Santvoort
O. J. L. Loosveld
J. de Vos-Geelen
B. M. Zonderhuis
M. Y. V. Homs
G. van Tienhoven
M. G. Besselink
J. W. Wilmink
B. Groot Koerkamp
BMC Cancer, 21
[44] Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Janssen, Q. P.
van Dam, J. L.
Bonsing, B. A.
Bos, H.
Bosscha, K. P.
Coene, P. P. L. O.
van Eijck, C. H. J.
de Hingh, I. H. J. T.
Karsten, T. M.
van der Kolk, M. B.
Patijn, G. A.
Liem, M. S. L.
van Santvoort, H. C.
Loosveld, O. J. L.
De Vos-Geelen, J.
Zonderhuis, B. M.
Homs, M. Y., V
van Tienhoven, G.
Besselink, M. G.
Wilmink, J. W.
Koerkamp, B. Groot
BMC CANCER, 2021, 21 (01)
[45] A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer
Stinchcombe, Thomas E.
Peterman, Amy H.
Lee, Carrie B.
Moore, Dominic T.
Beaumont, Jennifer L.
Bradford, Daniel S.
Bakri, Kamal
Taylor, Mark
Crane, Jeffrey M.
Schwartz, Garry
Hensing, Thomas A.
McElroy, Edwin, Jr.
Niell, Harvey B.
Harper, Harry D.
Pal, Sridhar
Socinski, Mark A.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1569 - 1577
[46] Clinical Outcomes of the Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine Versus FOLFIRINOX
Choi, Y. J.
Kang, J. S.
Byun, Y.
Kim, H. S.
Han, Y.
Kim, H.
Kim, E.
Kwon, W.
Jang, J. Y.
PANCREAS, 2019, 48 (10) : 1414 - 1414
[47] Comparison of the efficacy of gemcitabine with capecitabine and gemcitabine with erlotinib combination chemotherapy in recurrent or advanced pancreatic cancer as first-line treatment: Single-center experience
Chun, S.
Lee, M.
Jeon, E.
An, H.
Hong, T.
You, Y.
Kim, D.
Lee, I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[48] CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Sinn, Marianne
Bahra, Marcus
Liersch, Torsten
Gellert, Klaus
Messmann, Helmut
Bechstein, Wolf
Waldschmidt, Dirk
Jacobasch, Lutz
Wilhelm, Martin
Rau, Bettina M.
Gruetzmann, Robert
Weinmann, Arndt
Maschmeyer, Georg
Pelzer, Uwe
Stieler, Jens M.
Striefler, Jana K.
Ghadimi, Michael
Bischoff, Sven
Doerken, Bernd
Oettle, Helmut
Riess, Hanno
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3330 - +
[49] Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine and radiation efficacy in borderline resectable (BR) pancreatic cancer.
Gupta, Niraj K.
Singh, Kirpal
Glass, Timothy
Davis, Chad
Lybik, Mark
Leagre, Christopher
Liebross, Robert H.
Dugan, Thomas
Edwards, Mark
Givens, Stanley
Compton, Julia
Tigges, Thomas
Flanders, Vincent
Mathavan, Vinay
Isch, Andrew
Reeves, Dave
Arevalo, Gabriel
Rowe, Michael
Kaderabek, Douglas
Arregui, Maurice
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50] Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
Park, Semi
Chung, Moon Jae
Park, Jeong Youp
Chung, Jae Bock
Bang, Seungmin
Park, Seung Woo
Song, Si Young
GUT AND LIVER, 2013, 7 (05) : 611 - 615

← 1 2 3 4 5 →